Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunol Res. 2010 Dec;48(1-3):84-98. doi: 10.1007/s12026-010-8169-7.

The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Author information

1
UCLA Department of Microbiology, Immunology and Molecular Genetics, UCLA AIDS Institute, 10940 Wilshire Blvd., Los Angeles, CA 90024-1678, USA. geoff.symonds@calimmuneinc.com

Abstract

HIV/AIDS is a disease that impairs immune function, primarily by decreasing T-lymphocyte count. Its progression can be contained by highly active antiretroviral therapy (HAART), but there are side effects that can be severe, and the development of resistance often forces the physician to modify the HAART regimen. There are no vaccines available for HIV. An alternative approach that could provide a path to a curative therapy is the use of cell-delivered gene therapy in which an anti-HIV gene(s) is introduced into hematopoietic cells to produce a population that is protected from the effects of HIV. In this paper, we review the field and discuss an approach using a short hairpin RNA to CCR5, an important co-receptor for HIV.

PMID:
20737298
DOI:
10.1007/s12026-010-8169-7
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center